A series of clinical assessment scales were used to determine if TREM2 p.R47H carriers exhibited differences in depression, anxiety, apathy, fatigue and quality of life compared to the clinical control and mild cognitive impairment group, who did not have the risk variant (Additional file 1: Table S5). Here, TREM2 is linked to Cognitive impairment.